The startup operates a market access platform that enables pharmaceutical companies and governments to plan, negotiate, and manage drug pricing agreements through a configurable infrastructure. This platform enhances global access to medicines by facilitating rational pricing and efficient rebate payment processes, ensuring patients receive necessary therapies.

FabricNano develops cell-free biomanufacturing processes that utilize biocatalysts and natural materials to produce sustainable products. This technology addresses the environmental impact of traditional manufacturing by enabling efficient, eco-friendly production methods.

Inoviv provides end‑to‑end targeted proteomics services for pharma and biotech companies, delivering pre‑validated or custom multiplexed LC‑MS biomarker panels that quantify proteins, PTMs, lipids, and metabolites with absolute accuracy down to pg/mL. Their CLIA‑ and GLP‑certified workflow includes sample preparation, proprietary standards, high‑throughput LC‑MS/MS analysis, and bioinformatics reporting, enabling rapid biomarker validation, treatment monitoring, patient stratification, and companion diagnostic development.

Limbo integrates wearable technology and artificial intelligence with a mobile application to provide real-time monitoring of weight loss efforts. The platform delivers personalized coaching and actionable insights, enabling users to track their progress and make informed health decisions.

This platform facilitates patient care by providing multilingual communication and streamlined management of the patient journey. It offers tools for patients to easily engage with their care and delivers actionable insights to healthcare teams for improved decision-making.

Multiomic Health develops precision medicines for diseases derived from metabolic syndrome by integrating multi-omics data with longitudinal clinical phenotyping. The company uses AI-enabled data science to identify distinct molecular disease drivers within patient subpopulations. This approach enables the origination of therapeutic R&D programs with corresponding patient-stratifying companion diagnostics for higher clinical trial success rates.

Nomagic develops intelligent robotic solutions for item handling in e-commerce and retail, utilizing advanced robotics, cloud technology, and deep learning to automate order fulfillment processes. Their systems achieve a throughput of 700 items per hour and can cover 90% of SKUs, resulting in cost reductions of up to 75% and a return on investment within two years.

Ochre Bio develops a deep phenotyping platform that utilizes human models to generate genomic and phenotypic data at scale, enabling the rapid development of RNA therapies for chronic liver disease. This approach addresses the rising prevalence of liver disease, which is a leading cause of premature death globally, by providing targeted treatments for patients with late-stage conditions.

Pear Bio utilizes computer vision to transform patient tumor biopsies into 3D immune-microtumors, enabling side-by-side testing of various treatment options to predict individual responses. This approach addresses the challenge of matching patients with effective therapies for hard-to-treat cancers while also identifying new therapeutic targets from excess tissue.

Phagos develops customizable bacteriophage therapies that target specific antibiotic-resistant bacteria, providing a rapid and effective alternative to traditional antibiotics. By harnessing the natural adaptability of bacteriophages, the company can create tailored solutions within two months to combat the growing threat of antimicrobial resistance.

Valink Therapeutics develops next-generation bispecific antibody-drug conjugates (ADCs) designed for enhanced tumor targeting and reduced off-target toxicity. Their proprietary V-Gate approach enables continuous, tunable drug activation based on multiple molecular targets present on cancer cells. This technology aims to create more effective oncology therapeutics capable of treating diseases resistant to current options.